ArticleBlood2022
Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Daprodustat augments red cell and γ-globin production in models of sickle cell disease.Blood red cells & iron · 2026Article
- Factors associated with hemoglobin response to hydroxyurea in patients with sickle cell disease.Blood red cells & iron · 2026Article
- Global Prevalence of Alloimmunization in Adults with Sickle Cell Disease Receiving Red Blood Cell Transfusions: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Molecular and therapeutic frontiers in anemia therapy.The Journal of clinical investigation · 2026Review
- Luspatercept ameliorates disease phenotype and complications in the Townes mouse model of sickle cell disease.The Journal of clinical investigation · 2026Article
- Prevalence and Predictors of Priapism Among Patients with Sickle Cell Disease: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Hemoglobin and human longevity: integrating oxygen transport, redox biology, and aging pathways - a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Haematological Profile of Patients with Sickle Cell Disease in the Acholi Sub-Region, Uganda.Journal of blood medicine · 2026Article
- Sickle cell disease: suspect, check, diagnose-practical tips for non-SCD experts to suspect and diagnose SCD in low-prevalence European settings.Frontiers in medicine · 2025Review
- Navigating the Interplay of Sickle Cell Vasculopathy and Moyamoya Cerebrovascular Changes: A Case Report.Cureus · 2024Article
- Maximizing longevity: erythropoietin's impact on sickle cell anaemia survival rates.Annals of medicine and surgery (2012) · 2024Review
- How I treat anemia in older adults.Blood · 2024Article
- Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease.Hematology. American Society of Hematology. Education Program · 2023Article
- Clinical and haematological characteristics of 38 individuals with Hb G-Makassar in Malaysia.EJHaem · 2023Article
- Management of Older Adults with Sickle Cell Disease: Considerations for Current and Emerging Therapies.Drugs & aging · 2023Review
- Comparisons of Severe Maternal Morbidity and Other Adverse Pregnancy Outcomes in Pregnant People With Sickle Cell Disease vs Anemia.JAMA network open · 2023Article
- Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease.Current therapeutic research, clinical and experimental · 2023Article
- Numb Chin Syndrome in Sickle Cell Disease: A Systematic Review and Recommendations for Investigation and Management.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hemolytic anemia and intermittent acute pain episodes are the 2 hallmark characteristics of sickle cell disease (SCD). Anemia in SCD not only signals a reduction of red cell mass and oxygen delivery, but also ongoing red cell breakdown and release of cell-free hemoglobin, which together contribute to a number of pathophysiological responses and play a key role in the pathogenesis of cumulative multiorgan damage. However, although anemia is clearly associated with many detrimental outcomes, it may also have an advantage in SCD in lowering risks of potential viscosity-related complications. Until recently, clinical drug development for SCD has predominantly targeted a reduction in the frequency of vaso-occlusive crises as an endpoint, but increasingly, more attention is being directed toward addressing the contribution of chronic anemia to poor outcomes in SCD. This article aims to explore the complex pathophysiology and mechanisms of anemia in SCD, as well as the need to balance the benefits of raising hemoglobin levels with the potential risks of increasing blood viscosity, in the context of the current therapeutic landscape for anemia in SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.